Latest Non Dilutive Funding News

Hartshead Resources has struck a pivotal Well Carry Agreement with RockRose Energy, securing full funding for its Phase C drilling costs while trimming its joint venture stake. The move also triggers a licence extension application amid UK regulatory delays.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

IRIS Metals has agreed to sell its Kookynie Gold Project to Arika Resources, securing cash and equity to fuel its lithium ambitions in the US. This strategic move realigns IRIS’s portfolio towards critical minerals while retaining exposure to Kookynie through Arika shares.

BluGlass Limited reported a 16% rise in revenue to $11.7 million for FY25, driven by key US Department of Defense contracts and new partnerships. However, the company’s net loss increased 8% to nearly $11 million amid ongoing R&D investment and operational scaling.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

European Metals Holdings has secured a crucial funding pathway to complete the Definitive Feasibility Study for its Cinovec Lithium Project, combining a A$3 million placement with non-dilutive refinancing options to meet its €5.39 million share of a €11 million cash call.

Nova Minerals has garnered strong support from Alaska’s Governor and the Australian Consular-General for its Estelle Gold and Critical Minerals Project, aligning with key infrastructure and national security priorities.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.